Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Express Scripts Projects Higher Spending In Inflammation, Diabetes, Cancer

Feb 07 2017

• By Joseph Haas

US dollars

Related Content

Here Comes Sun’s US Cost-Saving Gleevec Generic

Feb 05 2016

Express Scripts Adds Gilead’s <em>Harvoni</em> To 2017 Formularies

Dec 14 2016

Celltrion/Pfizer Inflectra Second US Biosimilar; Many Firsts

Apr 06 2016

FDA OK's 1st generic copycats of Otsuka's Abilify

Apr 29 2015

Nexium Generics: Ranbaxy’s Exclusivity Loss Is Teva’s Gain

Feb 04 2015

Gilead Sees Prospects For Declining HCV Revenues To Stabilize

Jul 28 2016

Rx Spending Growth Won’t Exceed 8% In Coming Years – Express Scripts

Mar 15 2016

AbbVie v. Amgen Round One: Humira Biosimilar Infringes 10 Patents, Suit Claims

Aug 05 2016

Related Companies

Express Scripts Holding Company

Johnson & Johnson

AbbVie Inc.

Amgen, Inc.

Bristol Myers Squibb Company

Sanofi

Eli Lilly and Company

Novartis AG

Gilead Sciences, Inc.

Merck & Co., Inc.

Additional Topics

Pricing Strategies Market Access Commercial BioPharmaceutical

More from Drug Pricing

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window